tbuckley/cabot-search huggingface dataset:
Primary and secondary genetic responses after folic acid-induced acute renal injury in the mouse.
Authors: J P Calvet, L J Chadwick
Journal: Journal of the American Society of Nephrology (1994)

Folic acid-induced acute renal injury results in dramatic changes in gene expression. Among the genes affected by folic acid treatment are the primary response genes, c-fos and c-myc, which are thought to function to initiate cell cycle events. In this report, changes in the expression of three other genes in response to folic acid injury have been investigated: ornithine decarboxylase, epidermal growth factor (EGF), and sulfated glycoprotein-2 (SGP-2). Renal injury was found to cause a rapid decrease in EGF mRNA, which remained absent for several days after the initial injury, gradually returning to normal levels over an approximately 3-wk regeneration and recovery period. Ornithine decarboxylase mRNA showed a similar decrease. In contrast, folic acid caused a rapid increase in SGP-2 mRNA, which peaked several days after treatment, decreasing to normal levels over the 3-wk period. The mRNAs for the primary response genes were superinduced in the injured kidneys in the presence of the protein synthesis inhibitor cycloheximide. In contrast, the changes in EGF and SGP-2 mRNA levels were blocked by cycloheximide, indicating that these responses required new protein synthesis during the first few hours after folic acid injury. The opposite but parallel responses in the expression of the EGF and SGP-2 genes suggest that their regulation is coupled to the initial injury-induced dedifferentiation and subsequent return to the fully differentiated state.
Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts
Authors: James S. Yeh, Jessica M. Franklin, Jerry Avorn, Joan Landon, Aaron S. Kesselheim
Journal: JAMA Internal Medicine (2016)

Pharmaceutical industry payments to physicians may affect prescribing practices and increase costs if more expensive medications are prescribed.Determine the association between industry payments to physicians and the prescribing of brand-name as compared with generic statins for lowering cholesterol.Cross-sectional linkage of the Part D Medicare prescriptions claims data with the Massachusetts physicians payment database including all licensed Massachusetts physicians who wrote prescriptions for statins paid for under the Medicare drug benefit in 2011.The exposure variable was a physician's industry payments as listed in the Massachusetts database. The outcome was the physician's rate of prescribing brand-name statins. We used linear regression to analyze the association between the intensity of physicians' industry relationships (as measured by total payments) and their prescribing practices, as well as the effects of specific types of payments.Among the 2444 Massachusetts physicians in the Medicare prescribing database in 2011, 899 (36.8%) received industry payments. The most frequent payment was for company-sponsored meals (n = 639 [71.1%]). Statins accounted for 1 559 003 prescription claims; 356 807 (22.8%) were for brand-name drugs. For physicians with no industry payments listed, the median brand-name statin prescribing rate was 17.8% (95% CI, 17.2%-18.4%). For every $1000 in total payments received, the brand-name statin prescribing rate increased by 0.1% (95% CI, 0.06%-0.13%; P < .001). Payments for educational training were associated with a 4.8% increase in the rate of brand-name prescribing (P = .004); other forms of payments were not.Industry payments to physicians are associated with higher rates of prescribing brand-name statins. As the United States seeks to rein in the costs of prescription drugs and make them less expensive for patients, our findings are concerning.
A Curated Database of Rodent Uterotrophic Bioactivity
Authors: Nicole C. Kleinstreuer, Patricia C. Ceger, David G. Allen, Judy Strickland, Xiaoqing Chang, Jonathan T. Hamm, Warren M. Casey
Journal: Environmental Health Perspectives (2015)

Background:Novel in vitro methods are being developed to identify chemicals that may interfere with estrogen receptor (ER) signaling, but the results are difficult to put into biological context because of reliance on reference chemicals established using results from other in vitro assays and because of the lack of high-quality in vivo reference data. The Organisation for Economic Co-operation and Development (OECD)-validated rodent uterotrophic bioassay is considered the "gold standard" for identifying potential ER agonists.Objectives:We performed a comprehensive literature review to identify and evaluate data from uterotrophic studies and to analyze study variability.Methods:We reviewed 670 articles with results from 2,615 uterotrophic bioassays using 235 unique chemicals. Study descriptors, such as species/strain, route of administration, dosing regimen, lowest effect level, and test outcome, were captured in a database of uterotrophic results. Studies were assessed for adherence to six criteria that were based on uterotrophic regulatory test guidelines. Studies meeting all six criteria (458 bioassays on 118 unique chemicals) were considered guideline-like (GL) and were subsequently analyzed.Results:The immature rat model was used for 76% of the GL studies. Active outcomes were more prevalent across rat models (74% active) than across mouse models (36% active). Of the 70 chemicals with at least two GL studies, 18 (26%) had discordant outcomes and were classified as both active and inactive. Many discordant results were attributable to differences in study design (e.g., injection vs. oral dosing).Conclusions:This uterotrophic database provides a valuable resource for understanding in vivo outcome variability and for evaluating the performance of in vitro assays that measure estrogenic activity.Citation:Kleinstreuer NC, Ceger PC, Allen DG, Strickland J, Chang X, Hamm JT, Casey WM. 2016. A curated database of rodent uterotrophic bioactivity. Environ Health Perspect 124:556–562; http://dx.doi.org/10.1289/ehp.1510183
Mechanical Circulatory Support and Rationale for Future Research—Reply
Authors: Prakash Deedwania, Tushar Acharya
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Early-life gut microbiome composition and milk allergy resolution
Authors: Supinda Bunyavanich, Nan Shen, Alexander Grishin, Robert Wood, Wesley Burks, Peter Dawson, Stacie M. Jones, Donald Y.M. Leung, Hugh Sampson, Scott Sicherer, Jose C. Clemente
Journal: Journal of Allergy and Clinical Immunology (2016)
Characteristics of paediatric patients with 2009 pandemic influenza A(H1N1) and severe, oxygen-requiring pneumonia in the Tokyo region, 1 September–31 October 2009
Authors: M Nishiyama, Y Yoshida, M Sato, M Nishioka, T Kato, T Kanai, T Ishiwata, H Wakamatsu, S Nakagawa, A Kawana, S Nonoyama
Journal: Eurosurveillance (2010)

Few reports describe the features of 2009 pandemic influenza A(H1N1) pneumonia in children. We retrospectively reviewed 21 consecutive children admitted to hospital from September to October 2009 in the Tokyo region. The diagnosis of 2009 pandemic influenza A(H1N1) virus infection was based on positive results of real-time RT-PCR or rapid influenza antigen test. All patients were hospitalised for pneumonia with respiratory failure and severe hypoxia. The median interval from onset of influenza symptoms to admission was 14 hours (range: 5-72 hours) and the median interval from the onset of fever (≥38 degrees C) to hospitalisation was 8.5 hours (range: 0-36 hours). All patients required oxygen inhalation. Four patients required mechanical ventilation. Chest radiography revealed patchy infiltration or atelectasis in all patients. Antiviral agents and antibiotics were administrated to all patients. Antiviral agents were administered to 20 patients within 48 hours of influenza symptom onset. No deaths occurred during the study period. Paediatric patients with this pneumonia showed rapid aggravation of dyspnoea and hypoxia after the onset of influenza symptoms.
Trans-Arterial Chemo-Embolization (Tace) with Cpt-11 Charged Microbeads in Metastatic Uveal Melanoma Patients: a Retrospective Analysis of 140 Patients with Liver Metastases
Authors: S. Valpione, M. Bazzi, C. Aliberti, R. Parrozzani, J. Pigozzo, P.L. Pilati, E. Midena, L.G. Campana, V. Chiarion-Sileni
Journal: Annals of Oncology (2014)
Biofeedback in the treatment of blepharospasm: a case study
Authors: G E Rowan, K Sedlacek
Journal: American Journal of Psychiatry (1981)

Although biofeedback has been of value in treating spastic paresis and torticollis, its effectiveness in other movement disorders is less clear. Blepharospasm, which has no definitive treatment, often has a strong psychogenic component. The authors report the use of electromyographic and temperature biofeedback in a women with blepharospasm who had responded poorly to psychotherapy. Her improvement during biofeedback treatment further elucidated psychogenic factors contributing to the disorder. At 3-months follow-up it seemed that the patient's secondary gain from the blepharospasm diminished the maximum treatment response she could have had to biofeedback.
Effect of Young Age on Outcomes in Pediatric Acute Promyelocytic Leukemia (APL): North American Intergroup Study CALGB 9710 (Alliance)
Authors: Matthew A. Kutny, Susan Geyer, Kristina M Laumann, John Gregory, Cheryl L. Willman, Wendy Stock, Richard A. Larson, Bayard L. Powell, James H. Feusner
Journal: Blood (2014)
Advanced Pancreatic Cancer: Adjuvant Anti-Tolerogenic Immunomodulation Improves Chemoimmunotherapy
Authors: E.M. Lasalvia-Prisco, P. Goldschmidt, F. Galmarini, J. Vazquez, E.E. Lasalvia-Galante, T. Carlevaro, J.C. Dau
Journal: Annals of Oncology (2014)
Morphologic Characterization of Proliferative Cells and Virus Particles in Turkeys With Lymphoproliferative Disease&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: K. Perk, M. Ianconescu, A. Yaniv, A. Zimber
Journal: JNCI Journal of the National Cancer Institute (1979)

The tumors found in turkeys having lymphoproliferative disease (LPD) are histologically characterized by a pleomorphic population of cells of the lymphoid series. Electron microscopy has shown that, despite marked differences in shape and size, the proliferating cells share basic ultrastructural features, indicating their lymphoid origin. Virus particles morphologically and morphogenetically characteristic of type C oncorna-viruses of Retraviridae were found in different organs and plasma samples of diseased or infected turkeys with LPD. This LPD type C virus resembled members of the reticuloendotheliosis virus group but not members of the avian sarcoma virus group.
The negligible effects of California's 1982 reform of the insanity defense test
Authors: M A McGreevy, H J Steadman, L A Callahan
Journal: American Journal of Psychiatry (1991)

The authors' goal was to determine whether changing the insanity test in California in 1982 actually affected use of the insanity defense.They gathered information on all individuals who entered the insanity plea (N = 1,300) and all those acquitted by reason of insanity (N = 665) in seven counties in California 3 years before and 3 years after the change in the test of insanity. They focused on whether California's revision of the insanity test affected the number and rate of insanity pleas, the number and rate of insanity acquittals, the characteristics of individuals using the defense, the target offenses, and the length of stay of insanity acquittees.The reform did not affect the rate of insanity pleas or acquittals, the characteristics of those using the defense, or their length of confinement.Although the reform had no direct effects on the use of the insanity defense, the authors hypothesize that an indirect change in criminal sentencing practices led to a decrease in the number and rate of insanity pleas and acquittals.
Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission
Authors: Ofir Wolach, Kristen E. Stevenson, Martha Wadleigh, Daniel J. DeAngelo, David P. Steensma, Karen K. Ballen, Robert J. Soiffer, Joseph H. Antin, Donna S. Neuberg, Vincent T. Ho, Richard M. Stone
Journal: American Journal of Hematology (2016)

Survival of patients ≥40 years of age with Philadelphia‐negative acute lymphoblastic leukemia (ALL) remains poor with current therapeutic approaches. It is unknown whether allogeneic hematopoietic stem‐cell transplantation (HSCT) in first remission confers a survival benefit compared to a chemotherapy‐only approach. We retrospectively compared the outcome of patients &gt;40 years treated with HSCT or chemotherapy alone in first remission ( n = 40 in each cohort). Three‐year overall survival (OS) and disease‐free survival (DFS) were not significantly different between the chemotherapy‐only and HSCT groups (OS, 46% [31–68] vs. 40% [27–59], P = 0.35; DFS, 31% [18–52] vs. 40% [27–59], P = 0.98). The 3‐year cumulative incidence of relapse (CIR) and non‐relapse mortality (NRM) were 61% [41–76] and 9% [2–21] for the chemotherapy‐only group and 28% [15–43] and 32% [17–47] for the transplant group (CIR, P = 0.011; NRM, P = 0.014). Allogeneic transplantation for patients ≥40 years with Ph‐negative ALL in first remission is associated with a lower CIR, but this benefit is offset by considerable NRM as compared with chemotherapy‐only approach. HSCT may be beneficial in patients with high‐risk disease features. Am. J. Hematol. 91:793–799, 2016. © 2016 Wiley Periodicals, Inc.
Pre-oxygenation with high-flow nasal cannula oxygen therapy and non-invasive ventilation for intubation in the intensive care unit
Authors: Emmanuel Besnier, Kévin Guernon, Michael Bubenheim, Philippe Gouin, Dorothée Carpentier, Gaëtan Béduneau, Steven Grangé, Pierre-Louis Declercq, Antoine Marchalot, Fabienne Tamion, Christophe Girault
Journal: Intensive Care Medicine (2016)
Case 33-1973
Authors: Richard C. Cabot, Benjamin Castleman, Robert E. Scully, Betty U. McNeely, Edward R. Wolpow, Edward P. Richardson, Benjamin Castleman
Journal: New England Journal of Medicine (1973)

Presentation of CaseA 77-year-old man was admitted to the hospital because of weakness.Five years previously congestive heart failure occurred, and atrial fibrillation was found. There was a single episode of difficulty in speaking that cleared after one week. For several years he had experienced intermittent Raynaud's phenomenon. Six months before entry dysphagia and constipation developed, and he lost 9 kg in weight, together with a decrease in peripheral edema. One month before admission there was the sudden onset of diplopia. There were episodes of numbness of the right side of the face and of the tongue, his voice . . .
HLA-Class I Alleles Impact Susceptibility To EBV+ Classical Hodgkin Lymphoma By Altering EBV Latent Antigen-Specific CD8+ T-Cell Immune Hierarchies
Authors: Maher K Gandhi, Rebekah M Brennan, Leesa Wockner, Pratip K Chattopadhyay, Mario Roederer, David A. Price, David K Cole, Brekhna Hassan, Konrad Beck, Alycia Thornton, David Gottlieb, David Ritchie, John F Seymour, Gayathri Kumarasinghe, Scott R Burrows, Kimberley Jones
Journal: Blood (2013)
Continuing Decrease in Hepatitis B Virus Infection 30 Years After Initiation of Infant Vaccination Program in Taiwan
Authors: Yen-Hsuan Ni, Mei-Hwei Chang, Chyi-Feng Jan, Hong-Yuan Hsu, Huey-Ling Chen, Jia-Feng Wu, Ding-Shinn Chen
Journal: Clinical Gastroenterology and Hepatology (2016)
IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).
Authors: Jean H. Hoffman-Censits, Petros Grivas, Michiel Simon Van Der Heijden, Robert Dreicer, Yohann Loriot, Margitta Retz, Nicholas J. Vogelzang, Jose Luis Perez-Gracia, Arash Rezazadeh, Sergio Bracarda, Evan Y. Yu, Christopher J. Hoimes, Joaquim Bellmunt, David I. Quinn, Daniel Peter Petrylak, Syed A. Hussain, Na Cui, Sanjeev Mariathasan, Oyewale O. Abidoye, Jonathan E. Rosenberg
Journal: Journal of Clinical Oncology (2016)

355 Background: The ORR and survival of mUC patients (pts) who progress after platinum-based chemotherapy (pctx) are poor. Atezolizumab (atezo) reinvigorates antitumor immunity by targeting PD-L1 and has shown promising Ph 1 activity in mUC. Methods: IMvigor 210 cohort 2 (NCT02108652) enrolled 316 mUC pts who progressed during or following pctx. Pts received atezo at 1200 mg IV q3w until loss of clinical benefit. The SP142 IHC assay centrally assessed PD-L1 expression. Pts/investigators were blinded to PD-L1 status. Co-primary endpoints were confirmed ORR by RECIST v1.1 per central review (IRF) and modified (m) RECIST per investigator, which were met if null hypothesis (ORR = 10%) was rejected (α = 5%). ORR endpoints were stratified by PD-L1 tumor-infiltrating immune cell (IC) status: IC2/3, IC1/2/3, all comers. Results: Efficacy/safety-evaluable pts (N = 311) had a median age of 66 y, CrCl &lt; 60 mL/min (35%) and ≥ 2 prior regimens for mUC (40%). Many had poor prognostic factors (Table). At 5/5/15 data cutoff (follow up ≥ 24 w), 43/47 responding pts had ongoing responses. Both IRF (Table) and mRECIST ORR correlated with IC status. Durable responses were seen including poor prognostic subgroups (Table). mDOR was not reached in any PD-L1 or prognostic subgroup. mPFS was 2.1 mo in all PD-L1 subgroups. Median treatment duration was 12 w (range 0-46). Treatment-related AEs (most commonly fatigue) occurred in 66% of pts (all Grade); 15% had G3-4 related AE and 4% had G3-4 immune-mediated AE. 27% of AEs led to dose interruption and 3% led to withdrawal. No renal toxicity was seen. Conclusions: IMvigor 210, the first Ph 2 study targeting PD-L1/PD-1 in mUC, demonstrated significantly improved ORR vs historic controls. Responses were durable and associated with higher PD-L1 IC expression; poor prognostic factors did not preclude response. Atezo was well tolerated, and a randomized Ph 3 study vs ctx is ongoing (IMvigor 211; NCT02302807). Clinical trial information: NCT02108652. [Table: see text]
Comparison of neoadjuvant chemotherapy (NACT) with 5-flurouracil, epirubicin (100mg), cyclophosphamide (FEC100) followed by docetaxel (D) (75mg) versus adriamycin and cyclophosphamide (AC) followed by docetaxel (100mg) in locally advanced breast cancer (LABC): A randomized clinical study.
Authors: Smita Kayal, Dubashi Biswajit, Sunu Lazar Cyriac, Bhawana Badhe, Kadambari D, Deepak Bharathi, Swaruparani D, Gopinath S, Dhanraj K
Journal: Journal of Clinical Oncology (2015)

e12002 Background: NACT in LABC improves the rate of breast conservation and pathological complete response (pCR), which could be a surrogate marker for chemo responsiveness and survival. In this study we compared pCR and toxicity between two regimens in a resource limited setting. Methods: Newly diagnosed LABC cases were enrolled between December 2012 and June 2014 and randomized into two arms. Arm A was AC (Adriamycin 60mg/m2, Cyclophosphamide 600mg/m2) 3 weekly for 4 cycles, followed by Docetaxel 100mg/m2 (with GCSF prophylaxis) for 3 weekly for 4 cycles and arm B was FEC 100 (5-flurouracil 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2) x 3 cycles Q 3 weekly followed by Docetaxel 75mg/m2 x 4 cycles Q 3 weekly. The primary end points were pCR and toxicity profile. Secondary endpoints were progression free survival (PFS) and overall survival(OS). Results: A total of 148 patients were enrolled (74 in each arm), treated and followed up for at least 6 months. Results are presented in table 1. No significant difference was observed between clinical and MRI documented complete response with pCR between the groups. In multivariate and univariate analysis none of the parameter (Age, Stage, Grade, Nodal status, hormonal and Her2 status) had a significant influence on the response in both the groups. Other grade 3 and 4 toxicities were comparable in both arms. Toxicity deaths were 2% in both groups. Conclusions: FEC(100) +D as neoadjuvant chemotherapy in LABC has similar pCR rates but with a significantly favorable toxicity profile as compared to AC+D. Parameters estimated Arm A (ACà D) N = 74(%) Arm B (FECàD) N = 74(%) p-Value Median age (in years) 48 52 - Stage III disease 60 (81%) 52 (70%) 0.18 Successful surgery 64 (87%) 67 (91%) 0.60 pCR 23 (31%) 25 (34%) 0.91 Grade 3/4 neutropenia 26 (35%) 12(16%) 0.01 Febrile neutropenia 25 (34%) 12 (16%) 0.02 Dose modifications 07 (10%) 05 (7%) 0.7 PFS (mean follow-up period = 23.9 months) 95.6% 97.9% 0.34 OS (mean follow-up period = 21.3 months) 82.4% 85.1% 0.34
Paclitaxel plus carboplatin: an effective combination chemotherapy for advanced non-small-cell lung cancer or just another Elvis sighting?
Authors: D H Johnson, L H Einhorn
Journal: Journal of Clinical Oncology (1995)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1995.13.8.1840 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 7636526 Paclitaxel plus carboplatin: an effective combination chemotherapy for advanced non-small-cell lung cancer or just another Elvis sighting? D H JohnsonxD H JohnsonSearch for articles by this author , L H EinhornxL H EinhornSearch for articles by this author https://doi.org/10.1200/JCO.1995.13.8.1840 First Page PDF © 1995 by American Society of Clinical Oncology
Assessing Myocardial Extracellular Volume by T1 Mapping to Distinguish Hypertrophic Cardiomyopathy From Athlete’s Heart
Authors: Peter P. Swoboda, Adam K. McDiarmid, Bara Erhayiem, David A. Broadbent, Laura E. Dobson, Pankaj Garg, Carrie Ferguson, Stephen P. Page, John P. Greenwood, Sven Plein
Journal: Journal of the American College of Cardiology (2016)